- Home
- KINS vs FENC Comparison
KINS vs FENC Comparison
Compare KINS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- FENC
- Stock Information
- Founded
- KINS 1886
- FENC 1996
- Country
- KINS United States
- FENC United States
- Employees
- KINS N/A
- FENC N/A
- Industry
- KINS Property-Casualty Insurers
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KINS Finance
- FENC Health Care
- Exchange
- KINS Nasdaq
- FENC Nasdaq
- Market Cap
- KINS 215.4M
- FENC 225.4M
- IPO Year
- KINS N/A
- FENC 2001
- Fundamental
- Price
- KINS $13.77
- FENC $8.76
- Analyst Decision
- KINS
- FENC Strong Buy
- Analyst Count
- KINS 0
- FENC 2
- Target Price
- KINS N/A
- FENC $13.50
- AVG Volume (30 Days)
- KINS 186.2K
- FENC 62.2K
- Earning Date
- KINS 10-28-2025
- FENC 11-06-2025
- Dividend Yield
- KINS 1.45%
- FENC N/A
- EPS Growth
- KINS 325.10
- FENC N/A
- EPS
- KINS 2.04
- FENC N/A
- Revenue
- KINS $183,702,376.00
- FENC $33,302,000.00
- Revenue This Year
- KINS $41.35
- FENC $0.96
- Revenue Next Year
- KINS $12.33
- FENC $51.71
- P/E Ratio
- KINS $6.79
- FENC N/A
- Revenue Growth
- KINS 28.36
- FENC N/A
- 52 Week Low
- KINS $8.36
- FENC $3.96
- 52 Week High
- KINS $22.40
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- KINS 46.40
- FENC 50.16
- Support Level
- KINS $13.15
- FENC $8.96
- Resistance Level
- KINS $14.17
- FENC $9.23
- Average True Range (ATR)
- KINS 0.52
- FENC 0.27
- MACD
- KINS 0.07
- FENC 0.00
- Stochastic Oscillator
- KINS 48.94
- FENC 34.57
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.